- Nachrichtendetail
-
26.04.2024 13:20:39 - dpa-AFX: Pfizer's Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia B
NEW YORK CITY (dpa-AFX) - Friday, Pfizer Inc. (PFE) announced that its gene
therapy Beqvez also known as fidanacogene elaparvovec-dzkt has been approved by
the FDA for treating adults with moderate to severe hemophilia B who undergo
regular prophylaxis and is facing a current life-threatening bleed.
The company indicated that the FDA's decision was influenced by data from the
BENEGENE-2 trial, a Phase 3 study that investigated the efficacy and safety of
Beqvez in adult males between 18 and 65 years old with moderately severe to
severe hemophilia B.
Pfizer also mentioned that Beqvez is undergoing evaluation by the European
Medicines Agency and has recently been given the green light in Canada.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
therapy Beqvez also known as fidanacogene elaparvovec-dzkt has been approved by
the FDA for treating adults with moderate to severe hemophilia B who undergo
regular prophylaxis and is facing a current life-threatening bleed.
The company indicated that the FDA's decision was influenced by data from the
BENEGENE-2 trial, a Phase 3 study that investigated the efficacy and safety of
Beqvez in adult males between 18 and 65 years old with moderately severe to
severe hemophilia B.
Pfizer also mentioned that Beqvez is undergoing evaluation by the European
Medicines Agency and has recently been given the green light in Canada.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
PFIZER INC. DL-,05 | 852009 | Frankfurt | 26,115 | 06.05.24 18:20:27 | +0,405 | +1,58% | 26,110 | 26,140 | 25,855 | 25,710 |
